Clinical features and risk factors of Raynaud’s phenomenon in primary Sjögren’s syndrome

Wei Lin 1 · Zhifei Xin 2 · Xiaoran Ning 1 · Yang Li 3 · Xiuying Ren 1 · Yashuang Su 1 · Meilu Liu 1 · Shaoying Guo 4 · Liu Yang 4 · Yixuan Liu 1 · Fengxiao Zhang 1 · Wen Zhang 5

Received: 1 February 2021 / Revised: 15 April 2021 / Accepted: 21 April 2021 / Published online: 29 April 2021 © The Author(s) 2021

Abstract

Objective The aim at the current study was to investigate the clinical characteristics and risk factors of Raynaud’s phenomenon (RP) in patients with primary Sjögren’s syndrome (pSS).

Methods Retrospective analysis of the medical records of 333 new-onset pSS patients was performed. Demographic, clinical, and serological data were compared between individuals with and without RP. Logistic regression analysis was used to identify risk factors.

Results RP was present in 11.41% of the pSS patients. pSS-RP patients were younger (49.74±14.56 years vs. 54.46±13.20 years, \( p = 0.04 \)) and exhibited higher disease activity (11 [5.75–15] vs. 7 [4–12], \( p = 0.03 \)) than those without. The prevalence of lung involvement was significantly higher in pSS patients with RP (60.53% vs. 17.29%; \( p < 0.001 \)). A significantly higher proportion of patients with pSS-RP tested positive about antinuclear (ANA), anti-RNP, and anti-centromere antibodies (ACA) compared to those without (\( p = 0.003, <0.001, \) and 0.01, respectively). Multivariate analysis identified lung involvement (odds ratio [OR]=8.81, 95% confidence interval [CI] 2.02–38.47; \( p = 0.04 \)), anti-RNP positive status (OR=79.41, 95% CI 12.57–501.78; \( p < 0.0001 \)), as well as ACA (OR=13.17, 95% CI 2.60–66.72; \( p = 0.002 \)) as prognostic factors for pSS-RP.

Conclusion The presence of RP defined a subset of pSS with a unique phenotype, manifesting as increased lung involvement and a higher frequency of anti-RNP antibodies and ACA, as well as greater disease activity. These results suggest that RP has clinical and prognostic value of pSS patients. Further prospective studies with a larger number of subjects are warranted to confirm our findings and assess the prognostic and treatment implications of RP in pSS patients.

Key Points

- Raynaud’s phenomenon (RP) was present in 38 (11.41%) of 333 patients with primary Sjögren’s syndrome (pSS), with patients with RP exhibiting a younger age and higher disease activity.
- The presence of RP indicates a subset of pSS with a unique phenotype, with manifestations including increased lung involvement and a higher frequency of anti-RNP antibodies and anti-centromere antibodies.
- Patients with pSS and RP need close follow-up and long-term observation (including assessment of microangiopathy), with specific attention paid to the possible development of clinical features of systemic sclerosis.

Lin Wei and Xin Zhifei contributed equally to this work.

Xiaoan Ning
HGHFMSMYK@163.com

Fengxiao Zhang
zfx9911@163.com

1 Department of Rheumatology and Immunology, Hebei General Hospital, No. 348 Heping West Road, Shijiazhuang 050051, Hebei, China
2 Department of Thoracic Surgery, Hebei General Hospital, Shijiazhuang 050051, China
3 Department of Oncology, Hebei General Hospital, Shijiazhuang 050051, China
4 Department of Graduate School, Hebei Medical University, Shijiazhuang 050017, China
5 Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases, State Key Laboratory of Complex Severe and Rare Diseases, Beijing 100730, China
Keywords Interstitial lung disease · Primary Sjögren’s syndrome · Raynaud’s phenomenon · Risk factors

Introduction

Primary Sjögren’s syndrome (pSS) is a chronic systemic autoimmune disease characterized by lymphocytic infiltration of the exocrine glands and circulating B-cell hyperactivity, with a wide range of organ-specific and systemic manifestation [1–5]. Dryness of the mouth and eyes is the most prevalent symptoms of the syndrome, while extraglandular disorders (including inflammatory arthritis, cutaneous lesions, and interstitial lung diseases) occur to approximately one-third of patients [6].

Raynaud’s phenomenon (RP) is essentially an exaggerated vasospastic response to cold exposure or stress, with the classic triphasic color change progressing from white (ischemia), from blue (de-oxygenation) to red (reperfusion) [7, 8]. Primary or secondary to several different conditions or causes, RP is often the initial manifestation of an underlying autoimmune connective tissue disease, such as systemic sclerosis (SSc), systemic lupus erythematosus (SLE), mixed connective tissue disease (MCTD), or Sjögren’s syndrome (SS) [9, 10]. Previous studies evaluating the prevalence of RP in patients with pSS have reported conflicting results with the prevalence ranges from 9 to 33% [11–14]. Additionally, some studies have linked the presence of RP to special clinical manifestations, including pulmonary hypertension (PH) and interstitial lung disease (ILD) [15].

Currently, it remains unknown whether the presence of RP represents a distinct subtype of the pSS. To the best of our knowledge, there are no reports describing the clinical features of comorbid pSS-RP in Chinese patients. We performed a retrospective study to investigate the prevalence, clinical characteristics, and immunological features of RP in patients with pSS.

Materials and methods

Study design and data collection

A total of 333 patients that received a new diagnosis of pSS between January 2016 and March 2019 in the inpatient Department of Rheumatology and Immunology of the Hebei General Hospital were retrospectively reviewed. The diagnosis of pSS was based on the 2002 American-European Consensus Group criteria [16]. Patients were divided into two groups according to the presence (pSS-RP cases) or absence (pSS controls) of RP. This study was approved by the Clinical Research Ethics Committee of the Hebei General Hospital (NO.2016070), and written informed consent for publication was obtained from the patients.

Data collection

Data regarding demographic, clinical, and serological profiles were retrospectively collected from medical records at the time of initial pSS diagnosis. The clinical information included age, disease duration, and systemic complications such as joint impairment, skin involvement, digestive involvement, renal dysfunction, neurological manifestations, pulmonary involvement, and hematological impairment [17, 18]. Laboratory findings included complete blood counts, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), serum immunoglobulins (Ig), complement 3 (C3), complement 4 (C4), rheumatoid factor (RF), and autoantibodies. Autoantibodies included ANA, anti-Sm, anti-RNP, anti-Ro/SSA, anti-La/SSB, and ACA. The samples of all tests were fresh blood, which were collected at first visit to our hospital. Additionally, the European League Against Rheumatism Sjögren’s Syndrome Disease Activity Index (ESSDAI) was used to evaluate disease activity of all pSS patients [19]. All data are available.

Statistical analysis

SPSS for Windows 25.0 statistical software package (IBM Corp., Armonk, NY, USA) was used for statistical analysis. Continuous variables were expressed as means and corresponding standard deviations for normally distributed data, with medians with 25–75th percentiles (Q25–Q75) used for presenting non-normally distributed data. Student’s t-test, chi-squared tests, and the Mann-Whitney U test were used for comparisons. Logistic regression analysis was performed to identify risk factors associated with RP in patients with pSS. We performed the analysis in two stages. First, we performed a monofactor analysis to examine differences between pSS patients with and without RP. Next, variables with p values ≤0.1 were entered into a multiple logistic regression analysis to provide adjusted estimations of the odds ratio (OR). OR with 95% confidence interval (95% CI) was calculated within the logistic regression analysis. In all statistical analyses, p < 0.05 was considered statistically significant.

Results

A total of 333 new-onset pSS patients were analyzed. In this series, 93.09% of patients were females, while 6.91% were males. Among the patients, 38 patients with pSS were complicated with RP, with a prevalence of 11.41%.
Demographic characteristics and immunological features of pSS patients with and without RP

Comparing pSS patients with and without RP, patients with RP were diagnosed at an earlier age (49.74±14.56 years) than patients without RP (54.46±13.20 years; \( p = 0.04 \)). No significant differences were found between the two groups in percentages of white blood cells as well as the subsets. While the circulating levels of RF and IgG were higher in patients with pSS and RP compared to patients without RP, the difference was not statistically significant. A significantly greater number of patients with pSS and RP were positive for ANA, ACA, and anti-RNP antibodies (\( p = 0.003, 0.01, \) and <0.001, respectively), while no significant differences were observed in other antibodies, such as anti-SSA, anti-SSB, and anti-Ro 52 (Table 1).

Clinical characteristics of pSS patients with RP

A comparison of clinical characteristics between pSS patients with and without RP is shown in Table 2. Significant differences were found for lung involvement (\( p < 0.001 \)), including ILD (\( p < 0.001 \)) and PAH (\( p = 0.03 \)), between the two subgroups. Additionally, leukopenia and lymphopenia were found more frequently in pSS patients with RP than in patients without RP (leukopenia: 31.58% vs. 17.63%, respectively, \( p = 0.04 \); lymphopenia: 34.21% vs. 25.42%, respectively, \( p = 0.25 \)). No significant differences were observed in renal, digestive, and nervous system involvement between the groups (\( p > 0.05 \)). Further, pSS patients with RP exhibited higher pSS disease activity (\( p = 0.03 \); Table 2).

Potential risk factors for RP development in patients with pSS

Multivariate logistic regression analysis was performed to identify the risk factors that can predict the development of RP in pSS patients (Table 3). Pulmonary and mucocutaneous involvement, ANA, anti-RNP antibodies, ACA, and variables found to be significantly different between pSS patients with and without RP were included in the assessment. Lung involvement (OR=8.81, 95% CI 2.02–38.47; \( p = 0.004 \)), the presence of circulating anti-RNP antibodies (OR=79.41, 95% CI 12.57–501.78; \( p < 0.001 \)), and ACA (OR=13.17, 95% CI 2.60–66.72; \( p = 0.002 \)) were found to be positively associated with RP in patients with pSS (Table 3). Other factors were not significantly related to the development of RP in pSS patients.

Discussion

In this study, for the first time, we investigated the differences of the specific clinical and immunological characteristics between pSS patients with and without RP, and evaluated the potential risk factors for comorbid pSS-RP in Chinese populations. RP was more common to people that experience disease onset of a younger age and in patients with severer pSS, including manifestations such as higher prevalence of lung damage (including ILD and PH). Additionally, this subgroup of patients with pSS is serologically marked by the presence of anti-RNP antibodies and ACA. Further, the involvement in lung tissue may be a risk factor of the development of RP.

With regard to the prevalence of RP in pSS patients, Youinou P et al. [12] previously described as 33.33% out of 45 pSS patients in France. Prevalence in our data (11.41%) was statistically lower than that of their data (\( p < 0.001 \) by chi-square test), but was comparable to the data from Spain reported by Garcia-Carrasco M et al. (12.5%, \( p = 0.67 \) by chi-square test) [14] and the data from Argentina reported by Demarchi J et al. (9.05%, \( p = 0.37 \) by chi-square test) [20]. Several factors account for the wide range of prevalence (data summarized in sup-Table 1) estimates of the literature. Notably, genetic has been indicated in the pathogenesis of RP. In 2000, Susol E. et al. conducted a genome-wide screen to identify chromosomal regions containing genes conferring susceptibility to RP, and identified three potential candidate genes: the beta subunit of the muscle acetylcholine receptor and the serotonin 1B and 1E receptors by a two-stage screening process [21]. Crispin JC et al. assessed the association between RP and single nucleotide polymorphisms (SNPs) in temperature-responsive or vaso-spatnic genes and found that RP was associated with variation in gene NOS1 [22]. Additionally, it has been suggested that MTHFR mutation is more frequently found in patients with RP, which confirms genetic predisposition may play a key role in the pathogenesis of RP [23]. What’s more, geographical factors may also lead to differences, because a colder climate may promote the development of RP [24]. Further, 37 of our 38 patients with pSS and RP were women, consistent with the results of other studies, showed that the incidence of RP in women was higher, suggesting that hormonal factors played an important role in the expression of this disorder. And some studies have found an association for RP and use of estrogen replacement therapy alone [25, 26].

A key finding in our study comes from the comparison of pSS disease activity between patients with and without RP. In the present study, we found the ESSDAI in patients with pSS and RP was significantly higher than in patients without RP. This finding contrasted to the report on Heimovski et al., who found lower disease activity score in SLE patients with RP [27]. In our current study, pSS-RP patients had more frequent extraglandular features compared to patients without RP, specifically lung involvement and cutaneous vasculitis. This observation is in line with previous published reports. Garcia-
Carrasco et al. reported a higher prevalence of articular involvement and cutaneous vasculitis [14] in pSS patients with RP, while Kraus et al. observed a higher frequency of non-erosive arthritis, vasculitis, and pulmonary fibrosis in patients with both pSS and RP [13]. Additionally, Roca et al. suggested that pSS patients with ILD more commonly exhibited RP [28]. Furthermore, RP was found to be associated with sensorimotor neuropathy and mononeuritis multiplex [29]. These reports show a similar pattern of extraglandular features, suggesting that pSS patients with RP comprise a subset with a homogeneous clinical presentation. Genetic predisposition was proposed as a potential contributor to the RP onset of pSS. Specifically, a subset of studies reported an increased frequency of HLA-DRw3 and HLA-DRw4 alleles [30] in patients with RP and pSS, which could partly account for the differences observed between pSS patients with and without RP.

Our results indicate that lung involvement may be a risk factor for the development of RP. Lung disorders, such as ILD, are common complications associated with autoimmune diseases, with very limited effective treatment strategies currently available [31]. In recent years, pSS patients with ILD were reported in some studies to exhibit RP more commonly [28], suggesting that an ischemic process may play a role in the development of lung damage. Furthermore, the results of our current study confirm the relationship between ILD and RP in pSS patients, expanding our understanding of the pathological mechanisms in ILD. Our findings indicate that assessment of microangiopathy should become an integral part of clinical evaluation of patients with pSS to allow the early detection of ILD or other fibrosis damage.

In addition, RP is associated with immunological disturbances. Previous published studies on immunological characteristics have provided conflicting information. Garcia-

| Table 1 Baseline characteristics of pSS patients with and without RP |
|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
|                | pSS with RP (n=38) | pSS without RP (n=295) | Unadjusted OR | 95% CI | p value |
| Demographic features |                |                |                |                |                |
| Gender (F/M) | 37:1 | 273:22 | 0.34 | 0.04–2.56 | 0.49 |
| Age (years)  | 49.74±14.56 | 54.46±13.20 | - | - | 0.04 |
| Duration (months) | 60 [24–120] | 48 [12–120] | - | - | 0.18 |
| Laboratory findings |                |                |                |                |                |
| White blood cell counts (×10^9/L) | 4.62 [3.58–6.23] | 4.97 [3.97–6.29] | - | - | 0.37 |
| Neutrophil counts (×10^9/L) | 2.84 [1.79–4.37] | 2.94 [2.21–4.25] | - | - | 0.36 |
| Lymphocyte counts (×10^9/L) | 1.42 [1.02–1.79] | 1.52 [1.10–1.87] | - | - | 0.54 |
| Hemoglobin (g/L) | 118 [109–133.75] | 122 [110–132] | - | - | 0.65 |
| Platelet counts (×10^9/L) | 200 [165.25–263.75] | 227 [179–270] | - | - | 0.31 |
| NLR | 1.78 [1.19–3.10] | 2.08 [1.43–2.91] | - | - | 0.47 |
| PLR | 148.42 [98.64–198.74] | 146.88 [110.56–206.92] | - | - | 0.75 |
| ESR (mm/1 h) | 18 [11.5–33] | 19 [8.25–36] | - | - | 0.98 |
| CRP (mg/L) | 2.67 [0.9–5.82] | 3.3 [1.12–4.29] | - | - | 0.83 |
| RF (IU/L) | 25.5 [10.60–68.85] | 16.2 [10.60–68.85] | - | - | 0.71 |
| IgG (g/L) | 16.50 [13.89–21.41] | 15.16 [12.10–19.65] | - | - | 0.13 |
| IgA (g/L) | 2.85 [1.99–3.72] | 2.06 [1.87–3.09] | - | - | 0.02 |
| IgM (g/L) | 1.17 [0.82–1.62] | 1.12 [0.74–1.60] | - | - | 0.51 |
| Elevated immunoglobulins (n, %) |                |                |                |                |                |
| RF (+) (n, %) | 14/38, 36.84% | 103/289, 35.64% | 1.04 | 0.51–2.09 | 0.88 |
| ANA (+) (n, %) | 20/35, 57.14% | 130/276, 47.10% | 1.50 | 0.74–3.05 | 0.26 |
| Anti-RNP (+) (n, %) | 37/97.37% | 226/76.83% | 11.30 | 1.52–83.85 | 0.003 |
| Anti-Ro52 (+) | 24/63.16% | 15/5.08% | 32.00 | 13.83–74.07 | <0.001 |
| Anti-La/SSA (+) (n, %) | 6/15.79% | 73/24.75% | 0.57 | 0.23–1.42 | 0.22 |
| ACA (+) (n, %) | 10/26.32% | 35/11.86% | 2.65 | 1.19–5.93 | 0.01 |
| Pathological of MSG with focus score ≥1 (n, %) | 36/37, 97.30% | 273/286, 95.45 | 1.71 | 0.22–13.50 | 1.0 |

pSS, primary Sjögren’s syndrome; RF, rheumatoid factor; ANA, antinuclear antibodies; MSG, minor salivary gland; ACA, anti-centromere antibodies; RNP, ribonucleoprotein. a Positive RF >20 IU/mL; b positive for ANA titers ≥1:320
Carrasco et al. reported a higher frequency of immunological markers in patients with SS and RP, primarily ANA and anti-Ro/SSA [14]. Conversely, other studies found no differences in immunological measures [11–13]. In our study, we noted the previously established association of RP with ANA, ACA, and anti-RNP autoantibodies, which were in agreement with two recent reports [32, 33]. A growing number of publications described the subgroup of pSS which displays a distinct serological profile characterized by the presence of ACA, which is well known to appear in CREST syndrome or limited cutaneous SSc patients [34]. ACA-positive pSS patients are more frequently affected by RP, peripheral neuropathy, and sclerodactyly, as compared to ACA-negative patients with pSS. Additionally, based on previous studies, pSS patients with positive ACA were regarded as a distinct clinical subgroup, showing intermediate features on classical pSS and limited cutaneous scleroderma (lSSc) [34]. Furthermore, Miyawaki et al. [35] reported that 6 out of 10 (60%) pSS patients with ACA and RP developed CREST syndrome in the long follow-up investigation, and it is necessary for us to follow up the present ACA-positive pSS-RP patients to determine whether they develop CREST syndrome in the long run. Although we excluded SSc in the present study according to the criteria [16], pSS complicated with SSc should be carefully examined during follow-up period. A prospective study for ACA-positive pSS-RP subset, with closer follow-up and more long-term observation, is needed to make mention of possibility for development to CREST syndrome or SSc.

There are several limitations on this study. We must first underline the size difference between the two groups. Even if we included 333 pSS patients, the largest number of cohort patients compared with the previous studies for pSS-RP, we had only 38 patients with RP. The relatively small size of RP patients might have lacked statistical power to show some differences and made it difficult to draw definite conclusions. Second, this is a retrospective, single-center study; the lack of clinical information on some patients may lead to unexpected various biases. Further prospective studies with a larger number of subjects are warranted to confirm our findings and assess the prognostic and treatment implications of RP in pSS patients.

In summary, our current findings confirm that observation of RP, despite being considered a non-specific cutaneous lesion, provides important information on the distinct systemic

| Variables                               | pSS with RP (n=38) | pSS without RP (n=295) | Unadjusted OR | 95% CI   | p value |
|----------------------------------------|--------------------|------------------------|---------------|----------|---------|
| Xerostomia (n, %)                      | 33 (86.84%)        | 257 (87.12%)           | 0.98          | 0.36–2.65 | 1.0     |
| Xerophthalmia (n, %)                   | 30 (78.95%)        | 216 (73.22%)           | 1.37          | 0.60–3.12 | 0.45    |
| Salivary gland enlargement (n, %)      | 6 (15.79%)         | 32 (10.85%)            | 1.54          | 0.60–3.97 | 0.41    |

| Systemic involvements (n, %)           |                    |                        |               |          |         |
|----------------------------------------|--------------------|------------------------|---------------|----------|---------|
| Hematological involvement              | 26 (68.42%)        | 159 (53.90%)           | 1.85          | 0.90–3.81 | 0.09    |
| Thrombocytopenia                       | 3 (7.89%)          | 17 (5.76%)             | 1.40          | 0.39–5.03 | 0.49    |
| Leukopenia                             | 12 (31.58%)        | 52 (17.63%)            | 2.16          | 1.02–4.55 | 0.04    |
| Lymphopenia                            | 13 (34.21%)        | 75 (25.42%)            | 1.53          | 0.74–3.13 | 0.25    |
| Hypocomplementemia                     | 10 (26.32%)        | 75 (25.42%)            | 1.07          | 0.50–2.30 | 0.91    |
| Arthritis                              | 20 (52.63%)        | 126 (42.71%)           | 1.49          | 0.76–2.93 | 0.25    |
| Lung involvement                       | 23 (60.53%)        | 51 (17.29%)            | 7.34          | 3.58–15.03| <0.001  |
| Interstitial lung disease               | 22 (57.89%)        | 44 (14.92%)            | 7.84          | 3.82–16.10| <0.001  |
| Pulmonary hypertension                 | 6 (15.79%)         | 16 (5.42%)             | 3.27          | 1.19–8.95 | 0.03    |
| Renal involvement                      | 1 (2.63%)          | 21 (7.12%)             | 0.35          | 0.05–2.70 | 0.49    |
| Digestive involvement                  | 2 (5.26%)          | 15 (5.08%)             | 1.04          | 0.23–4.72 | 1.0     |
| Nervous system involvement             | 2 (5.26%)          | 39 (13.22%)            | 0.37          | 0.08–1.58 | 0.20    |
| Musocutaneous involvement              | 38 (100%)          | 46 (15.59%)            | 1.81          | 1.49–2.19 | <0.001  |
| Lymphatic system involvement           | 7 (18.42%)         | 26 (8.81%)             | 2.34          | 0.94–2.19 | 0.08    |
| ESSDAI                                 | 11 [5.75–15]       | 7 [4–12]               | -             | -        | 0.03    |

Table 3 Multivariate analysis of features predicting RP in pSS patients

| Features                          | p value | Adjusted OR | 95% CI |
|-----------------------------------|---------|-------------|--------|
| ANA positive                      | 0.23    | 4.54        | 0.39–52.85 |
| Anti-RNP positive                 | <0.001  | 79.41       | 12.57–501.78 |
| ACA positive                      | 0.002   | 13.17       | 2.60–66.72 |
| Pulmonary involvement             | 0.004   | 8.81        | 2.02–38.47 |

CI, confidence interval; OR, odds ratio
and immunological profiles of this subcategory of patients with pSS. The detection of RP allows for the establishment of a disease subgroup in which patients experience pSS with an onset of a younger age and a more severe clinical presentation, including manifestations such as higher prevalence of lung damage (including ILD and PH). Additionally, this subgroup of patients with pSS is serologically marked by the presence of anti-RNP and ACA. Furthermore, the involvement of lung tissue may be a risk factor of the development of RP, which suggests a number of potential treatment targets. Further large-scale prospective studies are warranted to confirm these findings.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s10067-021-05749-w.

Author contribution Conception and design: Zhang Fengxiao, Ning Xiaoran, Zhang Wen; acquisition of data: all authors; analysis and interpretation of data: Guo Shaoying, Yang Liu, Liu Yixuan; statistical analysis: Lin Wei, Xin Zhifei, Li Yang; drafting the article or revising it critically for important intellectual content: all authors; final approval of the version published: all authors. All the authors agreed with the publication.

Funding This work was funded by the grant from the National Nature Science Foundation of China (No. 81801630) and the National Nature Science Foundation of Hebei Province (No. H2018307047).

Data availability The datasets used or analyzed during the current study are available from the corresponding author on reasonable request.

Code availability Not applicable.

Compliance with ethical standards Written informed consent was obtained from all participants. The study was approved by the Hebei General Hospital medical ethics committee (NO.2016070).

Disclosures None.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this statutory regulation or exceeds the permitted use, you will need to obtain Creative Commons licence and your intended use is not permitted by credit line to the material. If material is not included in the article's Creative Commons licence, unless indicated otherwise in a

References

1. Fox RI (2005) Sjögren’s syndrome. Lancet 366:321–331. https://doi.org/10.1016/S0140-6736(05)66990-5
2. Cafaro G, Croia C, Argyropoulou OD, Leone MC, Orlandi M, Finamore F, Cecchettini A, Ferro F, Baldini C, Bartoloni E (2019) One year in review 2019: Sjögren’s syndrome. Clin Exp Rheumatol 37 Suppl 118:3–15
3. Lin W, Jin L, Chen H, Wu Q, Fei Y, Zheng W, Wang Q, Li P, Li Y, Zhang W, Zhao Y, Zeng XZ, Hang F (2014) B cell subsets and dysfunction of regulatory B cells in IgG4-related diseases and primary Sjögren’s syndrome: the similarities and differences. Arthritis Res Ther 16:R118. https://doi.org/10.1186/ar4571
4. Hamza N, Bos NA, Kallenberg CG (2012) B-cell populations and sub-populations in Sjögren’s syndrome. Presse Med 41:e475–e483. https://doi.org/10.1016/j.pmed.2012.05.021
5. Ibrahim HM (2019) B cell dysregulation in primary Sjögren’s syndrome: a review. Jpn Dent Sci Rev 55:139–144. https://doi.org/10.1016/j.jdsr.2019.09.006
6. Comnec D, Jamin C, Pers JO (2014) Sjögren’s syndrome: where do we stand, and where shall we go? J Autoimmun 51:109–114. https://doi.org/10.1016/j.jaut.2014.02.006
7. Devigire V, Hughes M (2019) Raynaud’s phenomenon. Br J Hosp Med (Lond) 80:658–664. https://doi.org/10.12968/hmed.2019.80.11.658
8. Pauling JD, Hughes M, Pope JE (2019) Raynaud’s phenomenon-an update on diagnosis, classification and management. Clin Rheumatol 38:3317–3330. https://doi.org/10.1007/s10067-019-04745-5
9. Herrick A, Muir L (2014) Raynaud’s phenomenon (secondary). BMJ Clin Evid 2014:1125–1132
10. Cutole M, Smith V, Forst DE, Khanna D, Herrick AL (2017) Points to consider-Raynaud’s phenomenon in systemic sclerosis. Rheumatology (Oxford) 56:v45–v48. https://doi.org/10.1093/rheumatology/kex199
11. Kraus A, Caballero-Uribe C, Jakez J, Villa AR, Alarcon-Segovia D (1992) Raynaud’s phenomenon in primary Sjögren’s syndrome. J Rheumatol 17:618–620
12. Youinou P, Penneel YL, Katsikis P, Jouquen J, Fauchert P, Le Goff P (1990) Raynaud’s phenomenon in primary Sjögren’s syndrome. Br J Rheumatol 29:205–207. https://doi.org/10.1093/rheumatology/29.3.205
13. Skopoulis FN, Talal A, Galanopoulou V, Tsampoulas CG, Drosos AA, Moutsopoulos HM (1990) Raynaud’s phenomenon in primary Sjögren’s syndrome. J Rheumatol 17:618–620
14. Garcia-Carrasco M, Siso A, Ramos-Casals M, Rosas J, de la Red G, Gil V, Lasterra S, Cervera R, Font J, Ingelmo M (2002) Raynaud’s phenomenon in primary Sjögren’s syndrome. Prevalence and clinical characteristics in a series of 320 patients. J Rheumatol 29:726–730
15. Kampolis CF, Fragkioudaki S, Mavragani CP, Zornopoulou A, Samakovili A, Moutsopoulos HM (2018) Prevalence and spectrum of symptomatic pulmonary involvement in primary Sjögren’s syndrome. Clin Exp Rheumatol 36(Suppl 112):94–101
16. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, Daniels TE, Fox PC, Fox RI, Kassan SS, Pillemer SR, Talal N, Weisman MH, European Study Group on Classification Criteria for Sjögren’s Syndrome (2002) Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 61:554–558. https://doi.org/10.1136/ard.61.6.554
17. Ramos-Casals M, Brito-Zeron P, Seror R, Bootma H, Bowman SJ, Dorner T, Gottenberg JE, Mariette X, Theander E, Bombardieri S, De Vita S, Mandl T, Ng WF, Kruize A, Tzioufas A, Vitali C, Force ESST (2015) Characterization of systemic disease in primary Sjögren’s syndrome: EULAR-SS Task Force recommendations for articular, cutaneous, pulmonary and renal involvements. Rheumatology (Oxford) 54:2230–2238. https://doi.org/10.1093/rheumatology/kev200
18. Seror R, Theander E, Brun JG, Ramos-Casals M, Valim V, Dörner T, Bootsma H, Tzioufas A, Solans-Laquè R, Mandl T, Gottenberg J-E, Hachulla E, Sivils KL, Ng W-F, Fauchais A-L, Bombardieri S, Valesini G, Bartoloni E, Saraux A, Tomsic M, Sumida T, Nishiyama S, Caporali R, Kruize AA, Vollenweider C, Ravaud P, Vitali C, Mariette X, Bowman SJ (2015) Validation of EULAR primary Sjögren’s syndrome disease activity (ESSDAI) and patient indexes (ESSPRI). Ann Rheum Dis 74:859–866. https://doi.org/10.1136/annrheumdis-2013-204615

19. Seror R, Ravaud P, Bowman SJ, Baron G, Tzioufas A, Theander E, Gottenberg J-E, Bootsma H, Mariette X, Vitali C (2010) EULAR Sjögren’s syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjögren’s syndrome. Ann Rheum Dis 69:1103–1109

20. Demarchi J, Papasidero S, Medina MA, Klajn D, Chaparro Del Moral R, Rillo O, Martire V, Crespo G, Secco A, Catalan Pellet A, Amirrano C, Crow C, Asnal C, Pucci P, Caiero F, Benzanquen N, Pirola JP, Mayer M, Zazzetti F, Velez S, Barreira J, Tamborenea N, Santiago L, Raiti L (2017) Primary Sjögren’s syndrome: extraglandular manifestations and hydroxychloroquine therapy. Clin Rheumatol 36:2455–2460. https://doi.org/10.1007/s10067-017-3822-3

21. Suslo E, MacGregor AJ, Barrett JH, Wilson H, Black C, Welsh K, Silman A, Ollier B, Worthington J (2000) A two-stage, genome-wide screen for susceptibility loci in primary Raynaud’s phenomenon. Arthritis Rheum 43:1641–1646

22. Crispin JC, Munir S, Freidin MB, Brain S, Williams FMK (2018) Association of Raynaud’s phenomenon with a polymorphism in the NOS1 gene. PLoS One 13. https://doi.org/10.1371/journal.pone.0196279

23. Yalcin KS, Kosar A (2019) The frequency of Raynaud’s phenomenon in postmenopausal women. Clin Exp Rheumatol 19:10–11

24. Fraenkel L (2002) Raynaud’s phenomenon: epidemiology and risk factors. Curr Rheumatol Rep 4:123–128

25. Fraenkel L, Zhang Y, Chaisson CE, Evans SR, Wilson PWF, Felson DT (1998) The association of estrogen replacement therapy and the Raynaud phenomenon in postmenopausal women. Ann Intern Med 129:208–211

26. Wigley FM (2001) Raynaud’s phenomenon is linked to unopposed estrogen replacement therapy in postmenopausal women. Clin Exp Rheumatol 19:10–11

27. Heimovski FE, Simioni JA, Skare TL (2015) Systemic lupus erythematosus and Raynaud’s phenomenon. An Bras Dermatol 90:837–840. https://doi.org/10.1590/abd1806-4841.20153881

28. Roca F, Dominique S, Schmidt J, Smail A, Duhaut P, Levesque H, Marie I (2017) Intestinal lung disease in primary Sjögren’s syndrome. Autoimmun Rev 16:48–54. https://doi.org/10.1016/j.autrev.2016.09.017

29. Jamilouix Y, Magy L, Hurtevent JF, Gondran G, de Seze J, Launay D, Ly KH, Lambert M, Hachulla E, Hatron PY, Vidal E, Fauchais AL (2014) Immunological profiles determine neurological involvement in Sjögren’s syndrome. Eur J Intern Med 25:177–181. https://doi.org/10.1016/j.ejim.2013.10.005

30. Mann DL, Moutsopoulos HM (1983) HLA DR alloantigens in different subsets of patients with Sjögren’s syndrome and in family members. Ann Rheum Dis 42:533–536. https://doi.org/10.1136/ard.42.5.533

31. Ramos-Casals M, Brito-Zerón P, Bombardieri S, Bootsma H, De Vita S, Dörner T, Fisher BA, Gottenberg J-E, Hernandez-Molina G, Kocner A, Kostov B, Kruize AA, Mandl T, Ng W-F, Retamozo S, Seror R, Shoenfeld Y, Sisó-Almirall A, Tzioufas AG, Vitali C, Bowman S, Mariette X (2020) EULAR recommendations for the management of Sjögren’s syndrome with topical and systemic therapies. Ann Rheum Dis 79:3–18. https://doi.org/10.1136/annrheumdis-2019-216114

32. Tsukamoto M, Suzuki K, Takeuchi T (2018) Clinical and immunological features of anti-centromere antibody-positive primary Sjögren’s syndrome. Rheumatol Ther 5:499–505. https://doi.org/10.1007/s40744-018-0126-2

33. Park Y, Lee J, Koh JH, Cheo JY, Sung YK, Lee SS, Kim JM, Park SH, Kwok SK (2020) Clinical influences of anticientromere antibody on primary Sjögren’s syndrome in a prospective Korean cohort. Korean J Intern Med. https://doi.org/10.3904/kjim.2020.146

34. Lee KE, Kang JH, Lee JW, Wen L, Park DJ, Kim TJ, Park YW, Lee SS (2015) Anti-centromere antibody-positive Sjögren’s syndrome: a distinct clinical subgroup? Int J Rheum Dis 18:776–782. https://doi.org/10.1111/1756-185X.12684

35. Miyawaki S, Asanuma H, Nishiyama Y, Yoshinaga Y (2005) Clinical and serological heterogeneity in patients with anticientromere antibodies. J Rheumatol 32:1488–1494. https://doi.org/10.1007/s10067-020-05505-6

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.